Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant intraperitoneal catumaxomab in epithelial ovarian cancer surgery
2006-004484-54Phase 2Completed
- Sponsor
- Fresenius
- Start
- May 2007
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of catumaxomab in epithelial ovarian cancer (EOC), sponsored by Fresenius. Primary endpoint: Postoperative complication rate within 30 days. Started May 2007; status: completed.
02
Drugs
catumaxomab
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2006-004484-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004484-54.